These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 19031099

  • 1. Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients.
    Pachner AR, Brady J, Steiner I, Narayan K.
    J Neurol; 2008 Nov; 255(11):1815-7. PubMed ID: 19031099
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G.
    Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutralising antibodies to the beta interferons.
    Coles AJ.
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):110-1. PubMed ID: 12122161
    [No Abstract] [Full Text] [Related]

  • 9. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.
    Bertolotto A.
    Curr Opin Neurol; 2004 Jun; 17(3):241-6. PubMed ID: 15167056
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
    Hesse D, Frederiksen JL, Koch-Henriksen N, Schreiber K, Stenager E, Heltberg A, Ravnborg M, Bendtzen K, Sellebjerg F, Sorensen PS.
    Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-B antibodies in multiple sclerosis.
    Burks JS, Noronha A.
    Eur J Neurol; 2007 Jun; 14(6):e8-9; author reply e10-1. PubMed ID: 17539931
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comments on the report of the EFNS task force on IFN-beta antibodies in multiple sclerosis.
    Freedman MS.
    Eur J Neurol; 2007 Jun; 14(6):e7; author reply e10-1. PubMed ID: 17539930
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies.
    Mayr M, Berek K, Deisenhammer F.
    Eur J Neurol; 2003 Jul; 10(4):462-4. PubMed ID: 12823504
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.